Clinical trials: Heparin-induced Thrombocytopenia
- Condition Heparin-induced Thrombocytopenia
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Heparin-induced Thrombocytopenia Type II
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral…
- Trial name
- NCT00861692
- Testing
- argatroban
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Tanabe Pharma Corporation
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux.
- Trial name
- NCT01304238
- Testing
- lepirudin, danaparoid, argatroban
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline
Suspected Heparin-Induced Thrombocytopenia
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Compare Clinical Success and Costs in two Arms
- Trial name
- HIT (NCT00787332)
- Testing
- Desirudin or Argatroban®
- Where
- 24 sites in United States
- Volunteers
- 16 people
- Sponsor
- Canyon Pharmaceuticals, Inc.